Registration is now open for the virtual event Rethinking Alzheimer’s disease: Moving towards a new Alzheimer’s disease detection and diagnosis pathway in Sweden, taking place virtually on 26 September 2023 at 09:00 – 11:00.

The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Swedish Brain Foundation (SBF) and the Swedish Association of the Pharmaceutical Industry (LIF), will explore the ways we can rethink the Alzheimer’s care pathway, particularly in the Swedish healthcare context. 

Rethinking Alzheimer’s disease: Moving towards a new Alzheimer’s disease detection and diagnosis pathway in Sweden

The virtual event follows the launch of the Rethinking Alzheimer’s Disease White Paper: Detection & Diagnosis, looking at how to detect and diagnose the disease at an earlier stage (at mild cognitive impairment – MCI  – stage) and what new care pathways would need to be implemented to reach out to patients at that stage. Furthermore, with disease modifying treatments targeting patients with MCI potentially coming to market in the near future, it is important to see how prepared healthcare systems are to provide these new treatments.  

You can look forward to opening remarks from Prof. Suzanne Dickson (President, European Brain Council) and a keynote speech on daily life living with Alzheimer’s disease from a patient perspective.

The keynote will be followed by a panel discussion and Q&A From detection and diagnosis to innovative treatment and care, moderated by Joakim Ramsberg (Head of Science and Society, Swedish Brain Foundation). The panel will highlight the current challenges in Sweden with respect to Alzheimer’s disease early detection and diagnosis. The speakers will share perspectives on what can be done in Sweden to ensure people living with Alzheimer’s can get access to a timely, accurate diagnosis.

The second keynote address Rethinking the Alzheimer’s care pathway in Sweden will emphasise the importance of greater education and awareness that can support detection and diagnosis of Alzheimer’s in Sweden.

The event will conclude with a panel discussion and Q&A Healthcare system transformation: scaling up health systems’ readiness, which will explore what actions can be taken now to prepare health systems to provide more timely, accurate AD diagnosis.

Practical information

Date: Tuesday, 26 September 2023
Time: 09:00 – 11:00 (Brussels time)
Location: livestream
Registration: Please register here

All participants must register before attending this event. Once registered, Zoom instructions will be sent via email closer to the date.

Rethinking Alzheimer's disease - Virtual event - Sweden - 26 September 2023 - Programme

Save the date for the virtual event Rethinking Alzheimer’s disease: Moving towards a new Alzheimer’s disease detection and diagnosis pathway in Sweden, set to take place on 26 September 2023 at 10:00 – 12:00 (Brussels time)!

About Alzheimer’s disease

Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase before symptoms occur. It is the underlying cause in 70% of people with dementia. Dementia, which is not a specific disease but an overall term that describes a group of symptoms, is characterised by a decline in memory, thinking, behaviour and the ability to perform everyday activities.

It is estimated that 7 million people in Europe alone already live with Alzheimer’s disease and dementia. With a rapidly ageing population, it is a growing public health concern worldwide as this number is projected to rise to a staggering 14 million by 2030.

Rethinking Alzheimer’s disease: Moving towards a new Alzheimer’s disease detection and diagnosis pathway in Sweden

The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Swedish Brain Foundation (SBF) and the Swedish Association of the Pharmaceutical Industry (LIF), will explore the ways we can rethink the Alzheimer’s care pathway, particularly in the Swedish healthcare context. 

The virtual event follows the launch of the Rethinking Alzheimer’s Disease White Paper: Detection & Diagnosis, looking at how to detect and diagnose the disease at an earlier stage (at mild cognitive impairment – MCI  – stage) and what new care pathways would need to be implemented to reach out to patients at that stage. Furthermore, with disease modifying treatments targeting patients with MCI potentially coming to market in the near future, it is important to see how prepared healthcare systems are to provide these new treatments.  

The programme will feature keynote speeches on daily life living with Alzheimer’s disease and how we can rethink the Alzheimer’s care pathway, a panel discussion featuring key opinion leaders and experts involved in the Rethinking Alzheimer’s disease project, and much more. Follow the EBC social media channels (Twitter, LinkedIn) and dedicated newsletter for all the latest updates – more information coming soon!

Registration is now open for the launch event of the RETHINKING Alzheimer’s disease White Paper, taking place virtually on 24 January 2023 at 12:30 – 14:00.

The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper is the first of EBC’s “RETHINKING Alzheimer’s disease” project, looking at how to improve the detection, diagnosis, care and monitoring of Alzheimer’s disease.

Moving Towards a new Alzheimer’s Disease diagnostic pathway in Europe

Our understanding of the progression of Alzheimer’s disease has improved significantly, leading to the development of advanced diagnostics and treatment approaches. To keep people living with Alzheimer’s disease in better health for longer, healthcare systems must be equipped to accurately diagnose the disease earlier and enable earlier access to treatment and support. 

We’re at a crossroads in the management of Alzheimer’s disease, with new potential treatments on the horizon. Current healthcare systems are not set up to diagnose and treat the condition early enough to realise the value of upcoming advanced therapeutics, and the benefits they could deliver for broader society.  

This must change now, with the support of clear policies that enable timely detection and timely clinical and accurate pathological diagnosis of Alzheimer’s disease. 

Rethinking the detection and diagnosis of Alzheimer’s disease

Join the discussion and learn why an accurate and timely diagnosis is so crucial to advancing the science and our understanding of Alzheimer’s. You can look forward to opening remarks from MEP Sirpa Pietikäinen (EPP, Finland) and a keynote speech highlighting the value of an early diagnosis from a patient perspective.

The keynote will be followed by a panel discussion, moderated by Laura Campo (Eli Lilly and Company), featuring experts involved in the RETHINKING Alzheimer’s disease project, Kristian Steen Frederiksen (European Academy of Neurology), Maria Teresa Ferretti (Women’s Brain Project) and Linus Jönsson (Karolinska Institutet). The panel will emphasise a clear need for new clinical pathways building bridges between all stakeholders to improve the current situation and prepare for the future.

The event will conclude with a high-level policy panel, moderated by Frédéric Destrebecq (European Brain Council), with MEP Tomislav Sokol (EPP, Croatia), MEP Deirdre Clune (EPP, Ireland), Andrzej Rys (Directorate-General for Health and Food Safety – DG SANTE, European Commission) and Dr. Neerja Chowdhary (World Health Organization).

Practical information

Date: Tuesday, 24 January 2023
Time: 12:30 – 14:00 (Brussels time)
Location: livestream
Registration: Please register here

All participants must register before attending this event. Once registered, Zoom instructions will be sent via email closer to the date.

RETHINKING Alzheimer's disease - Launch event of the White Paper - Programme

The launch event of the RETHINKING Alzheimer’s disease White Paper, calling for change in Alzheimer’s care, will take place virtually on 24 January 2023 at 12:30 – 14:00.

About Alzheimer’s disease

Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase before symptoms occur. It is the underlying cause in 70% of people with dementia. Dementia, which is not a specific disease but an overall term that describes a group of symptoms, is characterised by a decline in memory, thinking, behaviour and the ability to perform everyday activities.

It is estimated that 9.7 million people in Europe alone already live with Alzheimer’s disease and dementia. With a rapidly ageing population, it is a growing public health concern worldwide as this number is projected to rise to a staggering 14 million by 2030.

RETHINKING Alzheimer’s disease: Detection and diagnosis

The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper is the first of EBC’s “RETHINKING Alzheimer’s disease” project, looking at how to improve the detection, diagnosis, care and monitoring of AD.

The White Paper is particularly looking at how to detect and diagnose the disease at an earlier stage (at mild cognitive impairment – MCI  – stage) and what new care pathways would need to be implemented to reach out to patients at that stage. With disease modifying treatments targeting patients with MCI potentially coming to market in the near future, it is also important to see how prepared healthcare systems are to provide these new treatments.  

You can look forward to a keynote speech on the value of an early diagnosis, a panel discussion featuring experts involved in the RETHINKING Alzheimer’s disease project, a policy panel with key stakeholders at the European Parliament and the European Commission and much more. Follow the EBC social media channels (Twitter, LinkedIn) and dedicated newsletter for all the latest updates – more information coming soon!